Moreover, a series of underlying clinical parameters, including (a) chronic infections, (b) cancer, and (c) metabolic conditions, must also be thoroughly scrutinized among cardiovascular disease patients to facilitate the combinatorial therapies together with PD-1 or PD-L1 agonist therapy. Here, CD274 is linked to cardiovascular disorder.